| BKNG |
Report |
Room nights |
IN-LINE |
pred ~318M vs. cons 317M |
MEDIUM |
| BKNG |
Report |
Gross bookings |
IN-LINE |
pred ~$49.3B vs. cons $49.0B |
MEDIUM |
| BKNG |
Report |
Adjusted EBITDA |
BEAT |
pred ~$2.61B vs. cons $2.55B |
MEDIUM |
| BKNG |
Guide |
3Q26 room-night growth |
LOWER |
guide ~1%–3% vs. cons 4.5% (3Q26) |
MEDIUM |
| BKNG |
Guide |
3Q26 gross-bookings growth |
LOWER |
guide ~3%–5% vs. cons 7.0% (3Q26) |
MEDIUM |
| BKNG |
Guide |
3Q26 revenue growth |
LOWER |
guide ~3%–5% vs. cons 6.5% (3Q26) |
MEDIUM |
| BKNG |
Guide |
3Q26 adjusted EBITDA |
LOWER |
guide ~$3.86B–$3.94B vs. cons $4.05B (3Q26) |
MEDIUM |
| BKNG |
Guide |
FY26 adjusted EPS |
LOWER |
guide ~$8.65–$8.95 vs. cons $9.15 (FY26) |
MEDIUM |
| BKNG |
Return |
Day-1 residual (stock − beta × S&P 500) |
-8.0% |
— |
MEDIUM |
| BKNG |
Return |
5-day cumulative residual |
-10.5% (FOLLOW-THROUGH) |
A modest 2Q26 EBITDA beat (~$2.61B vs. ~$2.55B) is outweighed by a 3Q26 EBITDA guide (~$3.90B midpoint vs. $4.05B consensus) and FY26 adjusted-EPS reset (~$8.80 midpoint vs. $9.15 consensus); out-period estimate cuts should continue after an initial ~-8.0% residual reaction toward ~-10.5% over five days. |
MEDIUM |